Marken continues their expansion of services in Latin America, by augmenting their GMP Compliant depot network with the newly purpose-built Buenos Aires facility.
“The expansion of our services in Latin America enables our clients to better recruit in treatment naïve populations and work with previously unreachable investigator sites, assuring quality and regulatory documentation through the entire supply chain.” said Wes Wheeler, Marken’s Chief Executive Officer.
Marken is implementing their stated plan and aims to build the most advanced, fit for purpose clinical distribution network to serve the pharmaceutical community. The new Argentina depot builds on Marken’s current Latin America business, and enables the company to grow from its life sciences logistics platform. Marken is developing further depot facilities in Europe, Asia and the Americas.
The Argentina depot joins Marken’s Mexico and Singapore depots offering the full range of temperature controlled storage capabilities including: controlled ambient, refrigerated (2º-8ºC), frozen (-20ºC) as well as a secured area for controlled substances. Each of Marken’s depots provides drug and equipment distribution solutions including: Pick & Pack, relabeling services, reverse logistics, reconciliation and certified destruction. Additionally the network manages specimen kit distribution, interim specimen storage and management.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.